Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||NZV930 + PBF-509 + Spartalizumab|
Limited information is currently available on NZV930, a putative monoclonal antibody against NT5E (CD73) (Jul 2018).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NZV930||SRF373|SRF-373|SRF 373|NZV 930|NZV-930||Adenosine Targeting 16 CD73 Antibody 6||NZV930 is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 31461341).|
|PBF-509||Taminadenant|NIR178||Adenosine Targeting 16||Taminadenant (PBF-509) binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241, PMID: 28582704).|
|Spartalizumab||PDR001|PDR-001||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 66||Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03549000||Phase I||NZV930 + PBF-509 + Spartalizumab NZV930 + Spartalizumab NZV930 + PBF-509 NZV930||A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.||Recruiting|